Loopbaan van Konrad Glund
Eerdere bekende functies van Konrad Glund
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Algemeen Directeur | 01-01-2006 | 30-04-2018 |
| Oprichter | 25-07-1997 | 30-04-2018 | |
Prosidion Ltd.
 Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Corporate Officer/Principal | 01-08-2004 | - |
| Martin-Luther-Universität Halle-Wittenberg | Corporate Officer/Principal | - | - |
| IFB Halle GmbH | Algemeen Directeur | - | - |
| Oprichter | - | - |
Opleiding van Konrad Glund
| Martin-Luther-Universität Halle-Wittenberg | Doctorate Degree |
Statistieken
Internationaal
| Duitsland | 4 |
| Verenigd Koninkrijk | 2 |
Operationeel
| Chief Executive Officer | 2 |
| Founder | 2 |
| Corporate Officer/Principal | 2 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| VIVORYON THERAPEUTICS N.V. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Prosidion Ltd.
Prosidion Ltd. Pharmaceuticals: MajorHealth Technology Prosidion Ltd. manufactures products for treatment of metabolic diseases such as diabetes and obesity. The company's products include oral inhibitors of dipeptidyl peptidase, glycogen phosphorylase inhibitor and glucokinase activator. It was founded in 2003 and is headquartered in Oxford, UK | Health Technology |
| IFB Halle GmbH |
- Beurs
- Insiders
- Konrad Glund
- Ervaring
